Drug
Aav2 Haqp1 Concentration 1
Aav2 Haqp1 Concentration 1: highest development phase Phase 2, developed by MeiraGTx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- MeiraGTx
Trials
| Drug | Phase | Indication |
|---|---|---|
| AAV2-hAQP1 Concentration 1 NCT05926765 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands |
Latest
No recent events.
Follow Aav2 Haqp1 Concentration 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.